Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."
Under a license agreement, Biopredic will leverage Preci’s expertise and production capacity in sourcing primary hepatocytes, and combine with its own IP and know-how in cell pooling. The partnership will provide DMPK researchers access to large batches of high-performing suspended pooled hepatocytes with extended longevity from multiple donors.
Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."
Through this agreement, RaySearch acquires full ownership of all rights to the product DrugLog for its application in the field of oncology, including the measuring device, calibration parameters, source code, as well as intellectual property rights.
Anna Kazanchyan, MD, Founder and CEO of Saghmos Therapeutics. "We are very pleased to announce the Notice of Allowance for our second patent, which will enhance the long-term value of ST-62516. Saghmos continues to build its intellectual property estate."
The Callisto™ Sample Prep System offers programmable, precise, and plastic-free liquid manipulation with pre-optimized applications to support short- and long-read sequencing workflows. With a growing menu of library prep kits powered by Watchmaker Genomics' solutions, Volta Labs will continue to expand the universe of pre-optimized applications available through Callisto and enable labs to maximize advancements in sequencing.
The new HiFi library prep kits are expected to be available for purchase in the first quarter of 2024, with delivery planned early in the second quarter of 2024. Automated protocols will first be available on the Hamilton NGS STAR system, with qualified protocols on additional PacBio Compatible automation platform partners being added in the future. Kits contain enough volume for customers to develop their own automated methods notes PacBio.
“We believe that the NADMED method will advance science and medical practice by enabling larger and quicker clinical trials and in due course, diagnostics. NAD measuring should be seen as a first-line diagnostic tool in the future to fight for example degenerative diseases and metabolic disorders."
The collaboration aims to cGMP validate and commercialize a first-of-its-kind novel test to accurately determine multiple critical quality attributes of mRNA products by directly sequencing both the DNA template and the messenger RNA (mRNA).
BIOTRONIK notes Over the past decades, more than 20 clinical studies that enrolled over 4,000 patients have confirmed the safety and efficacy of DX Technology. This strong foundation of clinical evidence has recently been enriched by the MATRIX study results, the largest clinical evaluation of DX Technology to date. Results from the MATRIX study confirm under real-world conditions that DX, with Home Monitoring, allows for reliable, guideline-recommended remote monitoring of subclinical AF.
By using this website you agree to accept Medical Device News Magazine Privacy Policy
